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Hematopoietic stem-cell transplantation (HSCT) is used to treat patients with a number of cancers 
and hematological diseases, including acute myeloid leukemia (AML). AML is a cancer of white 
blood cells of the myeloid lineage, which accumulate in the bone marrow as immature blasts and 
disrupt normal blood cell development. One potential problem with HSCT is the possibility of donor 
cells detecting recipient cells as foreign and inducing graft-versus-host disease (GVHD). To prevent 
this, unrelated HSCT donors are matched to recipients based on ten alleles for the human leukocyte 
antigen (HLA). 
Natural killer (NK) cells are part of the innate immune system that mediates recognition of self 
antigens and that targets cells expressing non-self antigens for destruction. NK cells recognize HLA 
present on all cells through activator and inhibitor cell surface receptors, including killer-cell 
immunoglobulin-like receptors (KIRs). All KIRs are randomly expressed on NK cells, which are 
educated to self-HLA when they mature. KIRs vary genetically between people, and the balance of 
KIR activating and inhibiting signals regulates NK cell function. Donor NK cells mediate an 
antileukemic effect in HSCT recipients when inhibitory KIRs are mismatched for HLA type in 
transplants, since these cells will recognize the recipient leukemia cells as foreign. The mismatched 
donor NK cells can decrease the rate of relapse; however, the mismatched transplant also has an 
increased risk of GVHD. 
Activating KIRs can also mediate NK cell antileukemic effects by targeting cells with matched HLA 
between donor and recipient, with decreased risk of GVHD. In collaboration with researchers from 
Memorial Sloan Kettering, Drs. Ted Gooley, Effie Petersdorf, and Mari Malkki from the Clinical 
Research Division asked if the presence of the specific activating receptor KIR2DS1 in donors 
affected outcomes in AML patients receiving HSCT. KIR2DS1 is the only activating receptor that can 
either activate or tolerize NK cell function depending on the HLA interaction. In a retrospective study, 
clinical data and DNA genotyping was assessed for 1277 AML patients who received HSCT from 
unrelated donors matched for HLA-A, B, C, DR and DQ or with a single mismatch to minimize the 
contribution of inhibitor KIRs. Results indicated that patients who received HSCT from KIR2DS1-
postive donors had a significantly lower rate of relapse than KIR2DS1-negative donors, 26.5 percent  
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versus 32.5 percent respectively (95% CI, 0.61 to 0.96; P=0.02). 
KIR2DS1 recognizes HLA-C1 and HLA-C2 alleles. Previous published data showed that 
homozygous HLA-C2 tolerizes NK cell activation by KIR2DS1, decreasing NK cell function. In 
accordance, the antileukemic effect of KIR2DS1-positive donors was only mediated if those donors 
also had HLA-C1/C1 homozygous or HLA-C1/C2 heterozygous alleles, 24.9 percent relapse, versus 
donorHLA-C2/C2 homozygous alleles, 37.3 percent relapse (95% CI, 0.28 to 0.75; P=0.002). 
Recipients with HLA-C2/C2 had increased relapse rates, regardless of KIR2DS1 status, most likely 
due to causes independent of KIR2DS1. 
Activating KIR receptors are diverse within the population, and most people have multiple activating 
KIRs. Donors positive forKIR2DS1 are mostly positive for KIR3DS1 as well, yet KIR3DS1-positive 
status had no effect on AML relapse. However, KIR3DS1-positive donor cells decreased mortality, 
60.1% versus 66.9% for KIR3DS1-negative donor cells in agreement with a previous study. This 
suggests that activating KIRs could provide different mechanisms for improved HSCT outcomes. By 
assessing the presence of KIR and HLA interactions of transplant donor and recipients, whether 
inhibitory or activating, patient outcomes after HSCT may be improved. Future prospective trials will 
need to be organized to address this question. Importantly, NK cell protective effect is most effective 
in myeloid leukemias, no protection from relapse was observed by KIR2DS1-positive donors in 427 
transplant patients with acute lymphoblastic leukemia (ALL). 
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Image adapted from Velardi A., 2008. 
NK cell function is regulated by KIR interactions with 
matched HLA class I alleles. In the case for inhibitor 
KIRs, binding with matching HLA prevents donor NK 
cell activation to self. If HLA is mismatched in 
transplant recipient leukemic cells, NK cells are 
relieved from inhibition and induce cell lysis. For 
activating KIRs, donor NK cells that bind the matched 
HLA are activated and induce cell lysis of transplant 
recipient AML cells. KIR2DS1 is an activating NK cell 
receptor that decreases the relapse rate in AML 
transplant recipients with HLA-C1/C1 or HLA-C1/C2 
alleles. 
 
